cholestatic liver disease
Conditions
Interventions
Experimental group:Take berberine hydrochloride tablets at a fixed dose of 0.2 g before meals.
Control group:N/A
Sponsors
Department of Gastroenterology, Second Affiliated Hospital of Army Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1. Patients over the age of 18 with a definite diagnosis of cholestatic liver disease (ALP >= 1.5 times the upper limit of the normal value, GGT >= 3 times the upper limit of the normal value); 2. Willing to participate in this study and sign the informed consent.
Exclusion criteria
Exclusion criteria: 1. Have used microecological agents within 14 days before joining the group; 2. Chronic infections (such as tuberculosis, HIV infection and parasitic infection); 3. Neurological or mental diseases that hinder the effective implementation of informed consent or may interfere with the subjects' compliance with research procedures (for example, severe depression in the last two years, history of suicidal behavior in the last three months, etc.); 4. History of other mental diseases, including schizophrenia and bipolar disorder; 5. Patients who are allergic to berberine hydrochloride tablets and patients with hemolytic anemia; 6. Children with inherited glucose 6- phosphate dehydrogenase deficiency; 7. Pregnancy and lactation; 8. Those who have not signed the informed consent form and/or the research process has not been completely completed.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The neurotransmitter serotonin in the serum;The neurotransmitter serotonin in the serum; | — |
Secondary
| Measure | Time frame |
|---|---|
| Metabolites in faeces; | — |
Countries
China
Contacts
Public ContactYang Shiming
The Second Affiliated Hospital of Army Medical University
Outcome results
None listed